Hemo Organic

Which are the latest news on Hemo Organic?

Why is Hemo Organic Ltd falling/rising?

As of 10-Jun, Hemo Organic Ltd's stock price is Rs 22.27, unchanged from the previous close. The stock has shown significant upward momentum, with a 10.14% increase over the past week and a 70.13% rise in the last month, indicating strong investor interest despite minor fluctuations.

As of 10-Jun, Hemo Organic Ltd's stock price is currently at Rs 22.27, showing no change from the previous close. Despite this stability in the current price, the stock has demonstrated a significant upward trend over various periods. Over the past week, the stock has risen by 10.14%, and in the last month, it has increased by an impressive 70.13%. Year-to-date, the stock has gained 29.63%, and over the past year, it has surged by 111.89%. <BR><BR>Today's performance indicates that the stock has outperformed its sector by 4.94%, and it has been on a consecutive gain streak for the last three days, accumulating a total return of 15.43% during this period. Although the stock opened with a loss of 4.99% today, it reached an intraday high of Rs 22.29, reflecting a recovery from the initial dip. The stock is also close to its 52-week high, being only 0.99% away from Rs 22.51.<BR><BR>Moreover, Hemo Organic Ltd is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a strong upward momentum. Increased investor participation is evident, with delivery volume rising by 57.73% compared to the 5-day average. This suggests a growing interest in the stock, contributing to its overall positive performance despite the minor fluctuations observed today. <BR><BR>In summary, while there was a slight decline at the opening, the overall trend for Hemo Organic Ltd remains positive, supported by strong historical performance and increasing investor engagement.

What does Hemo Organic do?

Hemo Organic Ltd produces and sells white coal and ayurvedic medicines, operating as a Micro Cap company. As of March 2026, it reported net sales of 1 Cr and a net loss of 1 Cr, with a market cap of INR 7 Cr.

Overview:<BR>Hemo Organic Ltd is engaged in the production and sale of white coal and ayurvedic medicines, operating within the Trading & Distributors industry and classified as a Micro Cap company.<BR><BR>History:<BR>Incorporated in August 1992, Hemo Organic Ltd was formerly known as Dinesh Allorga Limited. The company initially focused on manufacturing chemicals but shifted its operations due to a pollution crisis. The latest quarterly results reported net sales and net profit for March 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 1 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: -1 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 7 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 15 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.87 <BR>Return on Equity: 78.00% <BR>Price to Book: -7.36 <BR><BR>Contact Details:<BR>Address: 8-A Gulnar Chinar-Gulnar Apart, V V Nagar Road Anand Gujarat : 388001 <BR>Tel: 91-2692-248535 <BR>Email: drdineshpatel@rediffmail.com <BR>Website: http://www.hemoorganic.com

Are Hemo Organic Ltd latest results good or bad?

Hemo Organic Ltd's latest results are concerning, showing a net loss of ₹0.51 crores in Q4 FY26, down from a profit of ₹0.37 crores last year, with revenue dropping 61.41% year-on-year. The company faces severe operational challenges and has a negative book value, indicating significant financial instability.

Hemo Organic Ltd's latest results are quite concerning. In Q4 FY26, the company reported a net loss of ₹0.51 crores, a significant decline from a profit of ₹0.37 crores in the same quarter last year. Additionally, revenue plummeted by 61.41% year-on-year to just ₹0.93 crores, marking a troubling trend after three consecutive quarters of zero sales.<BR><BR>The operating margin also deteriorated sharply, falling to -31.18% compared to a positive margin of 5.81% in the previous year. This indicates severe operational distress, as the company is struggling to manage its costs effectively while generating minimal revenue.<BR><BR>Moreover, Hemo Organic has a negative book value of ₹-0.44 per share, reflecting complete equity erosion, and its financial stability is in serious doubt. The company's operational challenges, combined with a lack of institutional investor confidence, suggest a very risky investment environment.<BR><BR>Overall, the results paint a grim picture of Hemo Organic's financial health, indicating that the company is facing significant operational and financial challenges.

Should I buy, sell or hold Hemo Organic Ltd?

When is the next results date for Hemo Organic Ltd?

The next results date for Hemo Organic Ltd is 29 May 2026.

The next results date for Hemo Organic Ltd is scheduled for 29 May 2026.

How has been the historical performance of Hemo Organic?

Hemo Organic has shown significant financial improvement from March 2024 to March 2025, with net sales rising from 0.02 Cr to 2.41 Cr and a turnaround in profitability, achieving a profit after tax of 0.16 Cr. However, the company faces challenges with increased total liabilities, which rose to 4.70 Cr.

Answer:<BR>The historical performance of Hemo Organic shows significant fluctuations in financial metrics over the years, particularly from March 2019 to March 2025.<BR><BR>Breakdown:<BR>Hemo Organic's net sales have seen a notable increase from Mar'24 at 0.02 Cr to Mar'25 at 2.41 Cr, marking a substantial growth. However, the total expenditure also rose sharply to 2.46 Cr in Mar'25 from 0.27 Cr in Mar'24, leading to an operating profit (PBDIT) of 0.02 Cr in Mar'25, a recovery from a loss of 0.25 Cr in the previous year. The profit before tax improved to 0.03 Cr in Mar'25, compared to a loss of 0.26 Cr in Mar'24, and the profit after tax turned positive at 0.16 Cr, reversing from a loss of 0.26 Cr. Despite these improvements, the company's total liabilities increased to 4.70 Cr in Mar'25 from 0.92 Cr in Mar'24, while total assets also rose to 4.70 Cr. The book value per share adjusted to -0.44 in Mar'25, an improvement from -0.91 in Mar'24. The earnings per share (EPS) showed a positive shift to 0.46 in Mar'25 from -0.75 in Mar'24, indicating a recovery in profitability. Overall, while Hemo Organic has made strides in revenue and profit metrics, it continues to face challenges with its liabilities and book value.

Who are the top shareholders of the Hemo Organic?

The top shareholders of Hemo Organic include Dineshbhai Shanabhai Patel with 15.49%, and the Indian Clearing Corporation Limited at 8.08%. Individual investors collectively own 71.11% of the shares, with no institutional holdings or pledged promoter shares reported.

The top shareholders of Hemo Organic include Dineshbhai Shanabhai Patel, who holds the largest stake at 15.49%. The highest public shareholder is the Indian Clearing Corporation Limited, with an ownership of 8.08%. Additionally, individual investors collectively hold a significant portion of the company, accounting for 71.11% of the shares. There are no institutional holdings or pledged promoter shares reported.

Is Hemo Organic overvalued or undervalued?

As of April 1, 2024, Hemo Organic's valuation has shifted to risky due to overvaluation indicated by a PE ratio of 3.75 and poor performance compared to peers, with its stock declining 83.96% over the past three years versus a 49.13% increase in the Sensex.

As of 1 April 2024, Hemo Organic's valuation grade has moved from does not qualify to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued based on its current metrics, with a PE ratio of 3.75, an EV to EBIT of -5.22, and a PEG ratio of 0.02, all of which suggest significant financial distress and poor profitability.<BR><BR>In comparison to its peers, Hemo Organic's valuation stands out negatively against companies like Altius Telecom, which has a PE ratio of 52.97 and is rated very attractive, and Sagility India, which is rated fair with a PE of 33.73. The stark contrast in these ratios highlights Hemo Organic's struggles within the trading and distribution industry. Additionally, the company's stock performance has lagged behind the Sensex, particularly over the past three years, where it has declined by 83.96% compared to a 49.13% increase in the index.

What is the technical trend for Hemo Organic?

As of June 2, 2025, Hemo Organic's trend is sideways with mixed signals: while the weekly and monthly MACD and Bollinger Bands show mild bullishness, daily moving averages indicate short-term weakness, resulting in overall market indecision.

As of 2 June 2025, the technical trend for Hemo Organic has changed from mildly bullish to sideways. The weekly MACD remains mildly bullish, while the monthly MACD is also mildly bullish, indicating some positive momentum. However, the daily moving averages are mildly bearish, suggesting short-term weakness. The Bollinger Bands are bullish on both weekly and monthly time frames, which supports the overall bullish sentiment. The KST shows a mixed picture with weekly mildly bullish and monthly mildly bearish readings. Both the Dow Theory and RSI indicate no clear trend. Overall, the current stance is neutral with mixed signals, reflecting indecision in the market.

how big is Hemo Organic?

As of Jun 06, Hemo Organic Ltd has a market capitalization of 4.00 Cr, with recent net sales of 2.41 Cr and a net profit of 0.16 Cr. The latest balance sheet shows shareholder's funds of -0.32 Cr and total assets of 0.92 Cr.

Market Cap: As of Jun 06, Hemo Organic Ltd has a market capitalization of 4.00 Cr, classifying it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest 4 quarters, Hemo Organic reported Net Sales of 2.41 Cr and a Net Profit of 0.16 Cr. This data is based on Standalone financials.<BR><BR>Balance Sheet Snapshot: The Standalone balance sheet for the latest annual period ending in Mar'24 shows Shareholder's Funds of -0.32 Cr and Total Assets of 0.92 Cr.

Who are in the management team of Hemo Organic?

As of March 2021, the management team of Hemo Organic includes Dineshbhai S Patel (Chairman & Managing Director), Sonal D Patel (Executive Director), Krushanakant R Patel (Independent Director), Sanjeev Lodha (Additional Independent Director), Siyona Jhnawar (Director), and Nishita Mayank Sanghvi (Company Secretary).

As of March 2021, the management team of Hemo Organic includes the following members:<BR><BR>1. Dineshbhai S Patel - Chairman & Managing Director<BR>2. Sonal D Patel - Executive Director<BR>3. Krushanakant R Patel - Independent Director<BR>4. Sanjeev Lodha - Additional Independent Director<BR>5. Siyona Jhnawar - Director<BR>6. Nishita Mayank Sanghvi - Company Secretary<BR><BR>These individuals play key roles in the governance and management of the company.

Has Hemo Organic declared dividend?

No Dividend History Available

Who are the peers of the Hemo Organic?

Hemo Organic's peers include Redington, MMTC, MSTC, Ravindra Energy, Saptak Chem &, and Chambal Brewer. Redington shows excellent management and growth, while Ravindra Energy has the highest 1-year return at 141.63%, and Hemo Organic's return is -4.95%.

Peers: The peers of Hemo Organic are Redington, MMTC, MSTC, Ravindra Energy, Saptak Chem &, and Chambal Brewer.<BR><BR>Quality Snapshot: Excellent management risk is observed at Redington, while Average management risk is found at MMTC and MSTC, and the rest have Below Average or do not qualify. Growth is Excellent at Redington, Below Average at MMTC and MSTC, while Ravindra Energy has Below Average growth, and Saptak Chem & does not qualify. In terms of Capital Structure, Excellent is noted at MSTC, Good at Redington, and the rest have Below Average or do not qualify.<BR><BR>Return Snapshot: Ravindra Energy has the highest 1-year return at 141.63%, while MSTC has the lowest at -39.89%. Hemo Organic's 1-year return is -4.95%, which is higher than MSTC's but lower than Ravindra Energy's. Additionally, MSTC and Chambal Brewer have negative six-month returns.